InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,745.37
(
0.40%
)
US TECH 100
19,572.00
(
0.72%
)
Dow Jones
42,175.11
(
0.62%
)
Brent Oil
70.77
(
-0.26%
)
Bitcoin
65,111.55
(
-0.11%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12535
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: Jesspro post# 55994

Sunday, 11/09/2014 12:35:00 PM

Sunday, November 09, 2014 12:35:00 PM

Post# of 80490
Jess, it wasn't one, it was three: Rida- was failure 1, Pona-was failure 2, '113-was failure 3 as they forced a high dose to try to cover EGFR and ALK+ at one time, dropped EGFR, then kept the dose too high for ALK+ so they had to stop the trial and start over, losing 18 precious months.

As 2da and others have commented, Ariad is a terrific research and discovery company, but really have no clue on how to bring a compound to the market. There is nothing wrong with this, you play to your strengths. The problem is the CEO is in never-never land and has a dream that Ariad is the next Celegene. That simply can not happen, and is dragging down the company.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up